- 2024,04,27
On the evening of April 25th, Cheng Yi Pharmaceutical released its 2023 annual report. In 2023, the company achieved a revenue of 672 million yuan, an increase of 2.54% compared to the same period last year; The net profit attributable to shareholders of the listed company was 163 million yuan, an increase of 0.81% compared to the same period last year. The company plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, with an expected cash distribution of 65.4609 million yuan, accounting for 40.19% of the net profit attributable to the parent company.
Public information shows that Cheng Yi Pharmaceutical has always attached great importance to giving back to investors through dividends. Since its listing in 2017, the company has adhered to annual dividends. As of now, the company has distributed dividends 6 times, with a cumulative dividend amount of 295 million yuan. The ratio of annual dividends to net profit for the year is over 30%.
High dividends cannot be separated from good performance. In 2023, Cheng Yi Pharmaceutical always adhered to the corporate philosophy of "diligence, frugality, rigor, innovation, and dedication", guided by the company's development strategy and annual business goals, continuously consolidated and strengthened the competitive advantage of its core business, and maintained a good development momentum in business performance.
In terms of sales, during the reporting period, Cheng Yi Pharmaceutical deeply cultivated the target markets and explored the potential of various product lines, continuously expanded the degree and depth of its marketing network, selected regional distributors and agents at all levels, and carried out maintenance and management of distributors and agents. The company fully explores the potential of new and old varieties, actively optimizes product structure, and continues to carry out analysis and optimization of product value chain; Actively participating in pharmaceutical bidding in various provinces across the country, the company's main product, Glucosamine Hydrochloride Capsules, has won bids in the vast majority of provinces. In addition, relying on the core business district of Shanghai Hongqiao, the company selects more outstanding marketing talents in the marketing center of the shipping camp, builds a marketing team that adapts to market changes, establishes a stronger global sales network, and accelerates the achievement of the company's marketing strategy goals.
During the reporting period, high-purity fish oil EPA health food and; The "Neuronic Acid" series products have been successfully launched; Guanchengbao ® Fish Oil Soft Capsule "Yi Kang Gu" ® Fish oil soft capsules; Complete the registration and listing of domestically produced health food; The registration of Thiazopurine Tablets for the treatment of leukemia has been approved. Subsidiary Huakang Pharmaceutical Co., Ltd. approved the listing of its aminosugar raw materials; The patented product "disposable negative pressure drainage kit" jointly developed and treated by the company and Shanghai Ruijin Hospital for pancreatic cancer was approved.
In terms of production, Cheng Yi Pharmaceutical has always adhered to the concept of "quality first" in drug production, implemented full process quality management, and implemented drug quality in all aspects from material procurement, production, inspection, storage, transportation, etc., strengthened risk process control, and maintained GMP normalized management. During the reporting period, the company organized special audits of raw and auxiliary material suppliers, strengthened on-site management of material suppliers, and ensured product quality from the source. Continuously conducted GMP training, fully promoted quality risk management, and continuously strengthened GMP management through supplier audits, production process monitoring, and other means.
In terms of research and development, during the reporting period, the company prioritized advantageous and profitable varieties, and carried out consistency evaluation work in a focused and planned manner. There are 5 varieties of oral solid preparations for consistency evaluation, among which the key varieties of azathioprine tablets have been approved, and the application for 20 carbon pentaenoic acid ethyl ester soft capsules, mercaptopurine tablets, and calcitriol soft capsules has been successfully accepted; Seven varieties of small volume injections have taken the lead in conducting consistency evaluations, among which 14 new products under development, including key varieties such as levocarnitine injection, lidocaine hydrochloride injection, citicoline sodium injection, and amikacin sulfate injection, have been successfully applied for and accepted. Among them, the raw material of voriconazole has been successfully applied for and accepted. As of the disclosure date of this report, the consistency evaluation of lidocaine hydrochloride injection has been approved.
Cheng Yi Pharmaceutical stated that the company will adhere to a product development strategy focused on marine medicine, traditional Chinese medicine, and biopharmaceuticals. Layout innovative drugs and big health-related products in areas such as the nervous system and endocrine system; On the basis of the successful transformation from raw materials to formulations, we will continue to promote the integrated competitive strategy of raw materials and formulation products, establish cost and scale advantages, and accelerate the development of characteristic generic drugs; Intensify the recruitment of talents, guided by clinical needs and market value, and develop safer and more effective new products.